AR and posterior cortical atrophy: Most prostate (primary) tumors in CRPC patients contain both AR+/hi and AR−/lo PCa cells and mCRPC patients harbor AR+/hi and AR−/lo metastatic clones2,32–34; therefore, curative anti-CRPC therapeutic strategies entail elimination of both PCa cell populations.